Related Experiment Video
Updated: Apr 18, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model
Roni Rak1, Roni Haklai1, Galit Elad-Tzfadia1
1Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel Aviv, Israel.
Abstract:
LIM kinases (LIMKs) are important cell cytoskeleton regulators that play a prominent role in cancer manifestation and neuronal diseases. The LIMK family consists of two homologues, LIMK1 and LIMK2, which differ from one another in expression profile, intercellular localization, and function. The main substrate of LIMK is cofilin, a member of the actin-depolymerizing factor (ADF) protein family. When phosphorylated by LIMK, cofilin is inactive. LIMKs play a contributory role in several neurodevelopmental disorders and in cancer growth and metastasis. We recently reported the development and validation of a novel LIMK inhibitor, referred to here as T56-LIMKi, using a combination of computational methods and classical biochemistry techniques. Here we report that T56-LIMKi inhibits LIMK2 with high specificity, and shows little or no cross-reactivity with LIMK1. We found that T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma. Because the most promising in-vitro effect of T56-LIMKi was observed in the pancreatic cancer cell line Panc-1, we tested the inhibitor on a nude mouse Panc-1 xenograft model. T56-LIMKi reduced tumor size and p-cofilin levels in the Panc-1 tumors, leading us to propose T56-LIMKi as a candidate drug for cancer therapy.
Insights
A novel inhibitor, T56-LIMKi, specifically targets LIMK2, a key regulator of cell cytoskeleton. This inhibitor reduced cancer cell growth and tumor size in preclinical models, suggesting its potential as a new cancer therapy.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- LIM kinases (LIMKs) regulate the cell cytoskeleton and are implicated in cancer and neurological disorders.
- LIMK2, a member of the LIMK family, phosphorylates cofilin, inactivating it and affecting actin dynamics.
- Dysregulation of LIMK-cofilin pathway contributes to cancer progression and metastasis.
Purpose of the Study:
- To develop and validate a novel LIMK inhibitor, T56-LIMKi.
- To investigate the specificity and efficacy of T56-LIMKi against LIMK2.
- To evaluate the therapeutic potential of T56-LIMKi in preclinical cancer models.
Main Methods:
- Computational methods and classical biochemistry for inhibitor development.
- In vitro assays to assess T56-LIMKi's inhibitory activity against LIMK2 and its effect on cancer cell lines (pancreatic cancer, glioma, schwannoma).
- In vivo studies using a nude mouse Panc-1 xenograft model to evaluate tumor growth inhibition.
Main Results:
- T56-LIMKi demonstrated high specificity for LIMK2 with minimal cross-reactivity with LIMK1.
- The inhibitor effectively decreased phosphorylated cofilin (p-cofilin) levels in various cancer cell lines.
- T56-LIMKi treatment significantly reduced tumor size and p-cofilin levels in a pancreatic cancer xenograft model.
Conclusions:
- T56-LIMKi is a potent and specific inhibitor of LIMK2.
- The findings support T56-LIMKi's potential as an anti-cancer therapeutic agent, particularly for pancreatic cancer.
- Further investigation of T56-LIMKi for cancer therapy is warranted.
